Using peptides to increase transport across the intestinal barrier

Advanced Drug Delivery Reviews

Volumn 106, Issue , 2016, Pages 355-366

  Sanchez Navarro M ^a   Garcia, J ^a   Giralt, E ^a,b   Teixido M ^a  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DELIVERY; MEDICINE;

ABSORPTION MECHANISMS; INTESTINAL ABSORPTION; INTESTINAL BARRIERS; ORAL ROUTE; PERMEATION ENHANCERS; POTENTIAL FORMULATIONS; TOXIC EFFECT;

PEPTIDES;

ACICLOVIR; BETA INTERFERON; CELL PENETRATING PEPTIDE; CHITOSAN; CYCLOSPORIN; CYCLOSPORIN A; EXENDIN 4; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; INSULIN; LEUPRORELIN; LEVOVIRIN; LIPOPOLYSACCHARIDE; LIPOSOME; MACROGOL; MANNITOL; MELITTIN; NANOPARTICLE; OCCLUDIN; OSELTAMIVIR; PARATHYROID HORMONE; PENETRATIN; PENETRATION ENHANCING AGENT; PEPTIDE; POLYARGININE; PROTAMINE; RITONAVIR; SALCATONIN; SAQUINAVIR; TRANSACTIVATOR PROTEIN; UNINDEXED DRUG; DRUG;

ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; CONJUGATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MIXTURE; DRUG TRANSPORT; HUMAN; IMMUNOGENICITY; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; LIPOSOMAL DELIVERY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; METABOLISM; ORAL DRUG ADMINISTRATION; PERMEABILITY; PHYSIOLOGY;

ADMINISTRATION, ORAL; ANIMALS; DRUG COMPOUNDING; HUMANS; INTESTINAL ABSORPTION; PEPTIDES; PERMEABILITY; PHARMACEUTICAL PREPARATIONS;

EID: 84975464498     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.04.031     Document Type: Review

References (142)

1. [1] Walsh, G., Biopharmaceutical benchmarks 2014. Nat. Biotechnol. 32 (2014), 992–1000.
2. [2] Leader, B., Baca, Q.J., Golan, D.E., Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 7 (2008), 21–39.
3. [3] Mitragotri, S., Burke, P.A., Langer, R., Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13 (2014), 655–672.
4. [4] Zhang, X., Wu, W., Ligand-mediated active targeting for enhanced oral absorption. Drug Discov. Today 19 (2014), 898–904.
5. [5] Maher, S., Brayden, D.J., Overcoming poor permeability: translating permeation enhancers for oral peptide delivery. Drug Discovery Today Technol. 9 (2012), e113–e119.
6. [6] Hwang, S.R., Byun, Y., Advances in oral macromolecular drug delivery. Expert Opin. Drug Deliv. 11 (2014), 1955–1967.
7. [7] des Rieux, A., Pourcelle, V., Cani, P.D., Marchand-Brynaert, J., Préat, V., Targeted nanoparticles with novel non-peptidic ligands for oral delivery. Adv. Drug Deliv. Rev. 65 (2013), 833–844.
8. [8] Yun, Y., Cho, Y.W., Park, K., Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv. Drug Deliv. Rev. 65 (2013), 822–832.
9. [9] Fosgerau, K., Hoffmann, T., Peptide therapeutics: current status and future directions. Drug Discov. Today 20 (2015), 122–128.
10. [10] Gentilucci, L., De Marco, R., Cerisoli, L., Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr. Pharm. Des. 16 (2010), 3185–3203.
11. [11] Shi, N.-Q., Qi, X.-R., Xiang, B., Zhang, Y., A survey on “trojan horse” peptides: opportunities, issues and controlled entry to “troy”. J. Control. Release 194 (2014), 53–70.
12. [12] Martín, I., Teixidó, M., Giralt, E., Building cell selectivity into CPP-mediated strategies. Pharmaceuticals, 3, 2010, 1456.
13. [13] Fernández-Carneado, J., Kogan, M.J., Castel, S., Giralt, E., Potential peptide carriers: amphipathic proline-rich peptides derived from the N-terminal domain of γ-zein. Angew. Chem. Int. Ed. 43 (2004), 1811–1814.
14. [14] del Pozo-Rodríguez, A., Pujals, S., Delgado, D., Solinís, M.A., Gascón, A.R., Giralt, E., Pedraz, J.L., A proline-rich peptide improves cell transfection of solid lipid nanoparticle-based non-viral vectors. J. Control. Release 133 (2009), 52–59.
15. [15] Martín, I., Teixidó, M., Giralt, E., Design, synthesis and characterization of a new anionic cell-penetrating peptide: SAP(E). Chembiochem 12 (2011), 896–903.
16. [16] Nevola, L., Giralt, E., Modulating protein–protein interactions: the potential of peptides. Chem. Commun. 51 (2015), 3302–3315.
17. [17] Pelay-Gimeno, M., Glas, A., Koch, O., Grossmann, T.N., Structure-based design of inhibitors of protein–protein interactions: mimicking peptide binding epitopes. Angew. Chem. Int. Ed. 54 (2015), 8896–8927.
18. [18] Nevola, L., Martín-Quirós, A., Eckelt, K., Camarero, N., Tosi, S., Llobet, A., Giralt, E., Gorostiza, P., Light-regulated stapled peptides to inhibit protein–protein interactions involved in clathrin-mediated endocytosis. Angew. Chem. Int. Ed. 52 (2013), 7704–7708.
19. [19] Guardiola, S., Díaz-Lobo, M., Seco, J., García, J., Nevola, L., Giralt, E., Peptides targeting egf block the EGF-EGFR interaction. ChemBioChem, 2016 (n/a-n/a).
20. [20] Malakoutikhah, M., Teixidó, M., Giralt, E., Shuttle-mediated drug delivery to the brain. Angew. Chem. Int. Ed. 50 (2011), 7998–8014.
21. [21] Prades, R., Oller-Salvia, B., Schwarzmaier, S.M., Selva, J., Moros, M., Balbi, M., Grazú, V., de La Fuente, J.M., Egea, G., Plesnila, N., Teixidó, M., Giralt, E., Applying the retro-enantio approach to obtain a peptide capable of overcoming the blood–brain barrier. Angew. Chem. Int. Ed. 54 (2015), 3967–3972.
22. [22] Arranz-Gibert, P., Guixer, B., Malakoutikhah, M., Muttenthaler, M., Guzmán, F., Teixidó, M., Giralt, E., Lipid bilayer crossing — the gate of symmetry. Water-soluble phenylproline-based blood–brain barrier shuttles. J. Am. Chem. Soc. 137 (2015), 7357–7364.
23. [23] Oller-Salvia, B., Sánchez-Navarro, M., Ciudad, S., Guiu, M., Arranz-Gibert, P., Garcia, C., Gomis, R.R., Cecchelli, R., García, J., Giralt, E., Teixidó, M., Miniap-4: a venom-inspired peptidomimetic for brain delivery. Angew. Chem. Int. Ed. 55 (2016), 572–575.
24. [24] Kaspar, A.A., Reichert, J.M., Future directions for peptide therapeutics development. Drug Discov. Today 18 (2013), 807–817.
25. [25] Tavelin, S., Hashimoto, K., Malkinson, J., Lazorova, L., Toth, I., Artursson, P., A new principle for tight junction modulation based on occludin peptides. Mol. Pharmacol. 64 (2003), 1530–1540.
26. [26] Mrsny, R.J., Brown, G.T., Gerner-Smidt, K., Buret, A.G., Meddings, J.B., Quan, C., Koval, M., Nusrat, A., A key claudin extracellular loop domain is critical for epithelial barrier integrity. Am. J. Pathol. 172 (2008), 905–915.
27. [27] Fasano, A., Fiorentini, C., Donelli, G., Uzzau, S., Kaper, J.B., Margaretten, K., Ding, X., Guandalini, S., Comstock, L., Goldblum, S.E., Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro. J. Clin. Invest. 96 (1995), 710–720.
28. [28] Kondoh, M., Masuyama, A., Takahashi, A., Asano, N., Mizuguchi, H., Koizumi, N., Fujii, M., Hayakawa, T., Horiguchi, Y., Watanbe, Y., A novel strategy for the enhancement of drug absorption using a claudin modulator. Mol. Pharmacol. 67 (2005), 749–756.
29. [29] Liu, P., Davis, P., Liu, H., Krishnan, T.R., Evaluation of cytotoxicity and absorption enhancing effects of melittin — a novel absorption enhancer. Eur. J. Pharm. Biopharm. 48 (1999), 85–87.
30. [30] Schwarze, S.R., Ho, A., Vocero-Akbani, A., Dowdy, S.F., In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 (1999), 1569–1572.
31. [31] Morishita, M., Kamei, N., Ehara, J., Isowa, K., Takayama, K., A novel approach using functional peptides for efficient intestinal absorption of insulin. J. Control. Release 118 (2007), 177–184.
32. [32] Higgins, L.M., Lambkin, I., Donnelly, G., Byrne, D., Wilson, C., Dee, J., Smith, M., O'Mahony, D.J., In vivo phage display to identify M cell-targeting ligands. Pharm. Res. 21 (2004), 695–705.
33. [33] Kang, S.K., Woo, J.H., Kim, M.K., Woo, S.S., Choi, J.H., Lee, H.G., Lee, N.K., Choi, Y.J., Identification of a peptide sequence that improves transport of macromolecules across the intestinal mucosal barrier targeting goblet cells. J. Biotechnol. 135 (2008), 210–216.
34. [34] Groschwitz, K.R., Hogan, S.P., Intestinal barrier function: molecular regulation and disease pathogenesis. J. Allergy Clin. Immunol. 124 (2009), 3–22.
35. [35] Tsukita, S., Furuse, M., Itoh, M., Multifunctional strands in tight junctions. Nat. Rev. Mol. Cell Biol. 2 (2001), 285–293.
36. [36] Wong, V., Gumbiner, B.M., A synthetic peptide corresponding to the extracellular domain of occludin perturbs the tight junction permeability barrier. J. Cell Biol. 136 (1997), 399–409.
37. [37] Zwanziger, D., Hackel, D., Staat, C., Böcker, A., Brack, A., Beyermann, M., Rittner, H., Blasig, I.E., A peptidomimetic tight junction modulator to improve regional analgesia. Mol. Pharm. 9 (2012), 1785–1794.
38. [38] Sonoda, N., Furuse, M., Sasaki, H., Yonemura, S., Katahira, J., Horiguchi, Y., Tsukita, S., Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: evidence for direct involvement of claudins in tight junction barrier. J. Cell Biol. 147 (1999), 195–204.
39. [39] Verma, D., Moghimi, B., LoDuca, P.A., Singh, H.D., Hoffman, B.E., Herzog, R.W., Daniell, H., Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 7101–7106.
40. [40] Nava, P., López, S., Arias, C.F., Islas, S., González-Mariscal, L., The rotavirus surface protein VP8 modulates the gate and fence function of tight junctions in epithelial cells. J. Cell Sci. 117 (2004), 5509–5519.
41. [41] Kondoh, M., Takahashi, A., Fujii, M., Yagi, K., Watanabe, Y., A novel strategy for a drug delivery system using a claudin modulator. Biol. Pharm. Bull. 29 (2006), 1783–1789.
42. [42] Takahashi, A., Kondoh, M., Uchida, H., Kakamu, Y., Hamakubo, T., Yagi, K., Mutated C-terminal fragments of Clostridium perfringens enterotoxin have increased affinity to claudin-4 and reversibly modulate tight junctions in vitro. Biochem. Biophys. Res. Commun. 410 (2011), 466–470.
43. [43] Suzuki, H., Kondoh, M., Kakutani, H., Yamane, S., Uchida, H., Hamakubo, T., Yagi, K., The application of an alanine-substituted mutant of the C-terminal fragment of Clostridium perfringens enterotoxin as a mucosal vaccine in mice. Biomaterials 33 (2012), 317–324.
44. [44] Kojima, T., Kondoh, M., Keira, T., Takano, K.-I., Kakuki, T., Kaneko, Y., Miyata, R., Nomura, K., Obata, K., Kohno, T., Konno, T., Sawada, N., Himi, T., Claudin-binder c-cpe mutants enhance permeability of insulin across human nasal epithelial cells. Drug Deliv., 2015, 1–8.
45. [45] Di Pierro, M., Lu, R., Uzzau, S., Wang, W., Margaretten, K., Pazzani, C., Maimone, F., Fasano, A., Zonula occludens toxin structure–function analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain. J. Biol. Chem. 276 (2001), 19160–19165.
46. [46] Huang, T.S., Lee, S.C., Lin, J.K., Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc. Natl. Acad. Sci. U. S. A. 88 (1991), 5292–5296.
47. [47] Fasano, A., Uzzau, S., Fiore, C., Margaretten, K., The enterotoxic effect of zonula occludens toxin on rabbit small intestine involves the paracellular pathway. Gastroenterology 112 (1997), 839–846.
48. [48] Fasano, A., Uzzau, S., Modulation of intestinal tight junctions by zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J. Clin. Invest. 99 (1997), 1158–1164.
49. [49] Cox, D.S., Gao, H., Raje, S., Scott, K.R., Eddington, N.D., Enhancing the permeation of marker compounds and enaminone anticonvulsants across Caco-2 monolayers by modulating tight junctions using zonula occludens toxin. Eur. J. Pharm. Biopharm. 52 (2001), 145–150.
50. [50] Cox, D.S., Raje, S., Gao, H., Salama, N.N., Eddington, N.D., Enhanced permeability of molecular weight markers and poorly bioavailable compounds across Caco-2 cell monolayers using the absorption enhancer, zonula occludens toxin. Pharm. Res. 19 (2002), 1680–1688.
51. [51] Salama, N.N., Fasano, A., Lu, R., Eddington, N.D., Effect of the biologically active fragment of zonula occludens toxin, ΔG, on the intestinal paracellular transport and oral absorption of mannitol. Int. J. Pharm. 251 (2003), 113–121.
52. [52] Salama, N.N., Fasano, A., Thakar, M., Eddington, N.D., The effect of ΔG on the transport and oral absorption of macromolecules. J. Pharm. Sci. 93 (2004), 1310–1319.
53. [53] Salama, N.N., Fasano, A., Thakar, M., Eddington, N.D., The impact of ΔG on the oral bioavailability of low bioavailable therapeutic agents. J. Pharmacol. Exp. Ther. 312 (2005), 199–205.
54. [54] Song, K.-H., Fasano, A., Eddington, N.D., Effect of the six-mer synthetic peptide (AT1002) fragment of zonula occludens toxin on the intestinal absorption of cyclosporin a. Int. J. Pharm. 351 (2008), 8–14.
55. [55] Li, M., Oliver, E., Kitchens, K.M., Vere, J., Alkan, S.S., Tamiz, A.P., Structure–activity relationship studies of permeability modulating peptide AT-1002. Bioorg. Med. Chem. Lett. 18 (2008), 4584–4586.
56. [56] Kauffman, W.B., Fuselier, T., He, J., Wimley, W.C., Mechanism matters: a taxonomy of cell penetrating peptides. Trends Biochem. Sci. 40 (2015), 749–764.
57. [57] Pujals, S., Fernandez-Carneado, J., Lopez-Iglesias, C., Kogan, M.J., Giralt, E., Mechanistic aspects of cell-penetrating peptide-mediated intracellular drug delivery: relevance of CPP self-assembly. Biochim. Biophys. Acta Biomembr. 1758 (2006), 264–279.
58. [58] Milletti, F., Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov. Today 17 (2012), 850–860.
59. [59] Fernández-Carneado, J., Kogan, M.J., Pujals, S., Giralt, E., Amphipathic peptides and drug delivery. Pept. Sci. 76 (2004), 196–203.
60. [60] Habermann, E., Bee and wasp venoms. Science 177 (1972), 314–322.
61. [61] Kamei, N., Morishita, M., Eda, Y., Ida, N., Nishio, R., Takayama, K., Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J. Control. Release 132 (2008), 21–25.
62. [62] Liang, J.F., Yang, V.C., Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem. Biophys. Res. Commun. 335 (2005), 734–738.
63. [63] Park, Y.J., Chang, L.-C., Liang, J.F., Moon, C., Chung, C.-P., Yang, V.C., Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB J., 2005.
64. [64] He, H., David, A., Zhang, J., Park, Y., Wang, J., Huang, Y., Wang, J., Yang, V., Low molecular weight protamine/insulin formulation with potential to attenuate protamine-masqueraded insulin allergy. Macromol. Res. 19 (2011), 1224–1226.
65. [65] He, H., Sheng, J., David, A.E., Kwon, Y.M., Zhang, J., Huang, Y., Wang, J., Yang, V.C., The use of low molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorption. Biomaterials 34 (2013), 7733–7743.
66. [66] Kamei, N., Kikuchi, S., Takeda-Morishita, M., Terasawa, Y., Yasuda, A., Yamamoto, S., Ida, N., Nishio, R., Takayama, K., Determination of the optimal cell-penetrating peptide sequence for intestinal insulin delivery based on molecular orbital analysis with self-organizing maps. J. Pharm. Sci. 102 (2013), 469–479.
67. [67] Khafagy, E.-S., Kamei, N., Nielsen, E.J.B., Nishio, R., Takeda-Morishita, M., One-month subchronic toxicity study of cell-penetrating peptides for insulin nasal delivery in rats. Eur. J. Pharm. Biopharm. 85 (2013), 736–743.
68. [68] Kamei, N., Onuki, Y., Takayama, K., Takeda-Morishita, M., Mechanistic study of the uptake/permeation of cell-penetrating peptides across a Caco-2 monolayer and their stimulatory effect on epithelial insulin transport. J. Pharm. Sci. 102 (2013), 3998–4008.
69. [69] Kristensen, M., de Groot, A.M., Berthelsen, J., Franzyk, H., Sijts, A., Nielsen, H.M., Conjugation of a cell-penetrating peptide to parathyroid hormone affects its structure, potency, and transepithelial permeation. Bioconjug. Chem., 2015.
70. [70] Khafagy, E.-S., Iwamae, R., Kamei, N., Takeda-Morishita, M., Region-dependent role of cell-penetrating peptides in insulin absorption across the rat small intestinal membrane. AAPS J. 17 (2015), 1427–1437.
71. [71] Curiel, T.J., Morris, C., Brumlik, M., Landry, S.J., Finstad, K., Nelson, A., Joshi, V., Hawkins, C., Alarez, X., Lackner, A., Mohamadzadeh, M., Peptides identified through phage display direct immunogenic antigen to dendritic cells. J. Immunol. 172 (2004), 7425–7431.
72. [72] Higgins, L., Lambkin, I., Donnelly, G., Byrne, D., Wilson, C., Dee, J., Smith, M., O'Mahony, D., In vivo phage display to identify m cell-targeting ligands. Pharm. Res. 21 (2004), 695–705.
73. [73] Fievez, V., Plapied, L., Plaideau, C., Legendre, D., des Rieux, A., Pourcelle, V., Freichels, H., Jérôme, C., Marchand, J., Préat, V., Schneider, Y.J., In vitro identification of targeting ligands of human M cells by phage display. Int. J. Pharm. 394 (2010), 35–42.
74. [74] Takagi, T., Arisawa, T., Yamamoto, K., Hirata, I., Nakano, H., Sawada, M., Identification of ligands binding specifically to inflammatory intestinal mucosa using phage display. Clin. Exp. Pharmacol. Physiol. 34 (2007), 286–289.
75. [75] Kim, S.-H., Lee, K.-Y., Kim, J., Park, S.-M., Park, B.K., Jang, Y.-S., Identification of a peptide enhancing mucosal and systemic immune responses against eGFP after oral administration in mice. Mol. Cell 21 (2006), 244–250.
76. [76] Staat, C., Coisne, C., Dabrowski, S., Stamatovic, S.M., Andjelkovic, A.V., Wolburg, H., Engelhardt, B., Blasig, I.E., Mode of action of claudin peptidomimetics in the transient opening of cellular tight junction barriers. Biomaterials 54 (2015), 9–20.
77. [77] Norsted, E., Gömüç, B., Meister, B., Protein components of the blood–brain barrier (BBB) in the mediobasal hypothalamus. J. Chem. Neuroanat. 36 (2008), 107–121.
78. [78] Goldblum, S.E., Rai, U., Tripathi, A., Thakar, M., De Leo, L., Di Toro, N., Not, T., Ramachandran, R., Puche, A.C., Hollenberg, M.D., Fasano, A., The active zot domain (aa 288–293) increases ZO-1 and myosin 1C serine/threonine phosphorylation, alters interaction between ZO-1 and its binding partners, and induces tight junction disassembly through proteinase activated receptor 2 activation. FASEB J. 25 (2011), 144–158.
79. [79] Gopalakrishnan, S., Pandey, N., Tamiz, A.P., Vere, J., Carrasco, R., Somerville, R., Tripathi, A., Ginski, M., Paterson, B.M., Alkan, S.S., Mechanism of action of ZOT-derived peptide AT-1002, a tight junction regulator and absorption enhancer. Int. J. Pharm. 365 (2009), 121–130.
80. [80] Song, K.-H., Fasano, A., Eddington, N.D., Enhanced nasal absorption of hydrophilic markers after dosing with 1002, a tight junction modulator. Eur. J. Pharm. Biopharm. 69 (2008), 231–237.
81. [81] Uchida, T., Kanazawa, T., Takashima, Y., Okada, H., Development of an efficient transdermal delivery system of small interfering rna using functional peptides, TAT and AT-1002. Chem. Pharm. Bull. 59 (2011), 196–201.
82. [82] Saaber, D., Wollenhaupt, S., Baumann, K., Reichl, S., Recent progress in tight junction modulation for improving bioavailability. Expert Opin. Drug Discovery 9 (2014), 367–381.
83. [83] Taverner, A., Dondi, R., Almansour, K., Laurent, F., Owens, S.-E., Eggleston, I.M., Fotaki, N., Mrsny, R.J., Enhanced paracellular transport of insulin can be achieved via transient induction of myosin light chain phosphorylation. J. Control. Release 210 (2015), 189–197.
84. [84] Jiao, C.-Y., Delaroche, D., Burlina, F., Alves, I.D., Chassaing, G., Sagan, S., Translocation and endocytosis for cell-penetrating peptide internalization. J. Biol. Chem. 284 (2009), 33957–33965.
85. [85] Martin, I., Teixido, M., Giralt, E., Intracellular fate of peptide-mediated delivered cargoes. Curr. Pharm. Des. 19 (2013), 2924–2942.
86. [86] Christiaens, B., Grooten, J., Reusens, M., Joliot, A., Goethals, M., Vandekerckhove, J., Prochiantz, A., Rosseneu, M., Membrane interaction and cellular internalization of penetratin peptides. Eur. J. Biochem. 271 (2004), 1187–1197.
87. [87] Zhu, X., Shan, W., Zhang, P., Jin, Y., Guan, S., Fan, T., Yang, Y., Zhou, Z., Huang, Y., Penetratin derivative-based nanocomplexes for enhanced intestinal insulin delivery. Mol. Pharm. 11 (2014), 317–328.
88. [88] Moreno, M., Giralt, E., Three valuable peptides from bee and wasp venoms for therapeutic and biotechnological use: melittin, apamin and mastoparan. Toxins 7 (2015), 1126–1150.
89. [89] Dempsey, C.E., The actions of melittin on membranes. Biochim. Biophys. Acta Rev. Biomembr. 1031 (1990), 143–161.
90. [90] Oren, Z., Shai, Y., Selective lysis of bacteria but not mammalian cells by diastereomers of melittin: structure–function study. Biochemistry 36 (1997), 1826–1835.
91. [91] Maher, S., Feighery, L., Brayden, D., McClean, S., Melittin as a permeability enhancer II: in vitro investigations in human mucus secreting intestinal monolayers and rat colonic mucosae. Pharm. Res. 24 (2007), 1346–1356.
92. [92] Enslin, G.M., Hamman, J.H., Kotzé, A.F., Intestinal drug absorption enhancers: synergistic effects of combinations. Drug Dev. Ind. Pharm. 34 (2008), 1343–1349.
93. [93] Huang, A., Su, Z., Li, S., Sun, M., Xiao, Y., Ping, Q., Deng, Y., Oral absorption enhancement of salmon calcitonin by using both N-trimethyl chitosan chloride and oligoarginines-modified liposomes as the carriers. Drug Deliv. 21 (2014), 388–396.
94. [94] Mitchell, D.J., Steinman, L., Kim, D.T., Fathman, C.G., Rothbard, J.B., Polyarginine enters cells more efficiently than other polycationic homopolymers. J. Pept. Res. 56 (2000), 318–325.
95. [95] Herce, H.D., Garcia, A.E., Cardoso, M.C., Fundamental molecular mechanism for the cellular uptake of guanidinium-rich molecules. J. Am. Chem. Soc. 136 (2014), 17459–17467.
96. [96] Nakase, I., Takeuchi, T., Tanaka, G., Futaki, S., Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides. Adv. Drug Deliv. Rev. 60 (2008), 598–607.
97. [97] Kamei, N., Morishita, M., Ehara, J., Takayama, K., Permeation characteristics of oligoarginine through intestinal epithelium and its usefulness for intestinal peptide drug delivery. J. Control. Release 131 (2008), 94–99.
98. [98] Maher, S., Kennelly, R., Bzik, V.A., Baird, A.W., Wang, X., Winter, D., Brayden, D.J., Evaluation of intestinal absorption enhancement and local mucosal toxicity of two promoters. I. Studies in isolated rat and human colonic mucosae. Eur. J. Pharm. Sci. 38 (2009), 291–300.
99. [99] Jin, Y., Song, Y., Zhu, X., Zhou, D., Chen, C., Zhang, Z., Huang, Y., Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 33 (2012), 1573–1582.
100. [100] Li, X., Wang, C., Liang, R., Sun, F., Shi, Y., Wang, A., Liu, W., Sun, K., Li, Y., The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles. Pharm. Res. 32 (2015), 1017–1027.
101. [101] Kraehenbuhl, J.-P., Neutra, M.R., Epithelial m cells: differentiation and function. Annu. Rev. Cell Dev. Biol. 16 (2000), 301–332.
102. [102] Kelsall, B.L., Strober, W., The role of dendritic cells in antigen processing in the Peyer's patch. Ann. N. Y. Acad. Sci. 778 (1996), 47–54.
103. [103] Yoo, M.-K., Kang, S.-K., Choi, J.-H., Park, I.-K., Na, H.-S., Lee, H.-C., Kim, E.-B., Lee, N.-K., Nah, J.-W., Choi, Y.-J., Cho, C.-S., Targeted delivery of chitosan nanoparticles to Peyer's patch using m cell-homing peptide selected by phage display technique. Biomaterials 31 (2010), 7738–7747.
104. [104] Mohamadzadeh, M., Duong, T., Sandwick, S.J., Hoover, T., Klaenhammer, T.R., Dendritic cell targeting of bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 4331–4336.
105. [105] Kathania, M., Zadeh, M., Lightfoot, Y.L., Roman, R.M., Sahay, B., Abbott, J.R., Mohamadzadeh, M., Colonic immune stimulation by targeted oral vaccine. PLoS One, 8, 2013, e55143.
106. [106] Kondoh, M., Takahashi, A., Yagi, K., Spiral progression in the development of absorption enhancers based on the biology of tight junctions. Adv. Drug Deliv. Rev. 64 (2012), 515–522.
107. [107] Scott Swenson, E., Curatolo, W.J., (c) Means to enhance penetration: (2) intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity. Adv. Drug Deliv. Rev. 8 (1992), 39–92.
108. [108] González-Mariscal, L., Tapia, R., Chamorro, D., Crosstalk of tight junction components with signaling pathways. Biochim. Biophys. Acta Biomembr. 1778 (2008), 729–756.
109. [109] Nusrat, A., Turner, J.R., Madara, J.L. IV, Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am. J. Physiol. Gastrointest. Liver Physiol. 279 (2000), G851–G857.
110. [110] Liu, X., Liu, C., Zhang, W., Xie, C., Wei, G., Lu, W., Oligoarginine-modified biodegradable nanoparticles improve the intestinal absorption of insulin. Int. J. Pharm. 448 (2013), 159–167.
111. [111] Nielsen, E.J.B., Kamei, N., Takeda-Morishita, M., Safety of the cell-penetrating peptide penetratin as an oral absorption enhancer. Biol. Pharm. Bull. 38 (2015), 144–146.
112. [112] Maher, S., McClean, S., Investigation of the cytotoxicity of eukaryotic and prokaryotic antimicrobial peptides in intestinal epithelial cells in vitro. Biochem. Pharmacol. 71 (2006), 1289–1298.
113. [113] Antonijevic, M.D., Craig, D.Q.M., Barker, S.A., The role of space charge formation in the generation of thermally stimulated current (TSC) spectroscopy data for a model amorphous drug system. Int. J. Pharm. 353 (2008), 8–14.
114. [114] Maher, S., Devocelle, M., Ryan, S., McClean, S., Brayden, D.J., Impact of amino acid replacements on in vitro permeation enhancement and cytotoxicity of the intestinal absorption promoter, melittin. Int. J. Pharm. 387 (2010), 154–160.
115. [115] Maher, S., Feighery, L., Brayden, D., McClean, S., Melittin as an epithelial permeability enhancer I: investigation of its mechanism of action in caco-2 monolayers. Pharm. Res. 24 (2007), 1336–1345.
116. [116] Maher, S., McClean, S., Melittin exhibits necrotic cytotoxicity in gastrointestinal cells which is attenuated by cholesterol. Biochem. Pharmacol. 75 (2008), 1104–1114.
117. [117] Walsh, E.G., Maher, S., Devocelle, M., O'Brien, P.J., Baird, A.W., Brayden, D.J., High content analysis to determine cytotoxicity of the antimicrobial peptide, melittin and selected structural analogs. Peptides 32 (2011), 1764–1773.
118. [118] Rosenmayr-Templeton, L., The oral delivery of peptides and proteins: established versus recently patented approaches. Pharm. Pat. Anal. 2 (2012), 125–145.
119. [119] Moroz, E., Matoori, S., Leroux, J.-C., Oral delivery of macromolecular drugs: where we are after almost 100 years of attempts. Adv. Drug Deliv. Rev. 101 (2016), 108–121.
120. [120] Maher, S., Leonard, T.W., Jacobsen, J., Brayden, D.J., Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. Adv. Drug Deliv. Rev. 61 (2009), 1427–1449.
121. [121] Nielsen, E.J.B., Yoshida, S., Kamei, N., Iwamae, R., Khafagy, E.-S., Olsen, J., Rahbek, U.L., Pedersen, B.L., Takayama, K., Takeda-Morishita, M., In vivo proof of concept of oral insulin delivery based on a co-administration strategy with the cell-penetrating peptide penetratin. J. Control. Release 189 (2014), 19–24.
122. [122] Carter, E., Lau, C.Y., Tosh, D., Ward, S.G., Mrsny, R.J., Cell penetrating peptides fail to induce an innate immune response in epithelial cells in vitro: implications for continued therapeutic use. Eur. J. Pharm. Biopharm. 85 (2013), 12–19.
123. [123] Dintzis, H.M., Symer, D.E., Dintzis, R.Z., Zawadzke, L.E., Berg, J.M., A comparison of the immunogenicity of a pair of enantiomeric proteins. Proteins Struct. Funct. Bioinform. 16 (1993), 306–308.
124. [124] Uppalapati, M., Lee, D.J., Mandal, K., Li, H., Miranda, L.P., Lowitz, J., Kenney, J., Adams, J.J., Ault-Riché, D., Kent, S.B.H., Sidhu, S.S., A potent D-protein antagonist of VEGF-A is nonimmunogenic, metabolically stable, and longer-circulating in vivo. ACS Chem. Biol. 11 (2016), 1058–1065.
125. [125] Hayashi, Y., Takayama, K., Suehisa, Y., Fujita, T., Nguyen, J.-T., Futaki, S., Yamamoto, A., Kiso, Y., Development of oligoarginine–drug conjugates linked to new peptidic self-cleavable spacers toward effective intestinal absorption. Bioorg. Med. Chem. Lett. 17 (2007), 5129–5132.
126. [126] Ramanathan, S., Pooyan, S., Stein, S., Prasad, P., Wang, J., Leibowitz, M., Ganapathy, V., Sinko, P., Targeting the sodium-dependent multivitamin transporter (SMVT) for improving the oral absorption properties of a retro-inverso TAT nonapeptide. Pharm. Res. 18 (2001), 950–956.
127. [127] Gupta, D., Varghese Gupta, S., Dahan, A., Tsume, Y., Hilfinger, J., Lee, K.-D., Amidon, G.L., Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue. Mol. Pharm. 10 (2013), 512–522.
128. [128] Li, F., Hong, L., Mau, C.-I., Chan, R., Hendricks, T., Dvorak, C., Yee, C., Harris, J., Alfredson, T., Transport of levovirin prodrugs in the human intestinal Caco-2 cell line. J. Pharm. Sci. 95 (2006), 1318–1325.
129. [129] Kamei, N., Morishita, M., Takayama, K., Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides. J. Control. Release 136 (2009), 179–186.
130. [130] Al-Hilal, T.A., Alam, F., Byun, Y., Oral drug delivery systems using chemical conjugates or physical complexes. Adv. Drug Deliv. Rev. 65 (2013), 845–864.
131. [131] Sung, E.B.K.L.A.H.-W., Nanoparticle- and biomaterials-mediated oral delivery for drug, gene and immunotherapy. Adv. Drug Deliv. Rev. 65 (2013), 757–902.
132. [132] Malhaire, H., Gimel, J.-C., Roger, E., Benoît, J.-P., Lagarce, F., How to design the surface of peptide-loaded nanoparticles for efficient oral bioavailability?. Adv. Drug Deliv. Rev. 106 (2016), 320–336.
133. [133] Shan, W., Zhu, X., Liu, M., Li, L., Zhong, J., Sun, W., Zhang, Z., Huang, Y., Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin. ACS Nano 9 (2015), 2345–2356.
134. [134] Muheem, A., Shakeel, F., Jahangir, M.A., Anwar, M., Mallick, N., Jain, G.K., Warsi, M.H., Ahmad, F.J., A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives. Saudi Pharm. J., 2014.
135. [135] Sukumar, M., Rizo, J., Wall, M., Dreyfus, L.A., Kupersztoch, Y.M., Gierasch, L.M., The structure of Escherichia coli heat-stable enterotoxin B by nuclear magnetic resonance and circular dichroism. Protein Sci. 4 (1995), 1718–1729.
136. [136] Vivès, E., Brodin, P., Lebleu, B., A truncated HIV-1 TAT protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272 (1997), 16010–16017.
137. [137] Futaki, S., Suzuki, T., Ohashi, W., Yagami, T., Tanaka, S., Ueda, K., Sugiura, Y., Arginine-rich peptides: an abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276 (2001), 5836–5840.
138. [138] Gehring, W.J., Affolter, M.A., Burglin, T., Homeodomain proteins. Annu. Rev. Biochem. 63 (1994), 487–526.
139. [139] Ando, T., Watanabe, S., A new method for fractionation of protamines and the amino acid sequences of salmine and three components of iridine. Int. J. Prod. Res. 1 (1969), 221–224.
140. [140] Byun, Y., Singh, V.K., Yang, V.C., Low molecular weight protamine: a potential nontoxic heparin antagonist. Thromb. Res. 94 (1999), 53–61.
141. [141] Lai, C.Y., Determination of the primary structure of cholera toxin b subunit. J. Biol. Chem. 252 (1977), 7249–7256.
142. [142] Pooga, M., Hällbrink, M., Zorko, M., Langel, U., Cell penetration by transportan. FASEB J. 12 (1998), 67–77.